Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 6, 2010, Pages

  Galaal, Khadra ^a   Naik, Raj ^b   Bristow, Robert E ^c   Patel, Amit ^d   Bryant, Andrew ^e   Dickinson, Heather O ^e  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST MICHAEL'S HOSPITAL   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER RECURRENCE; CANCER REGISTRY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CYTOREDUCTIVE SURGERY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; CARCINOMA; FEMALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 77954986199     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007822.pub2     Document Type: Review

References (45)

1. Harter P, Kurzeder C, du Bios A. A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer. ClinicalTrials.gov Identifier: NCT01166737 2012.
2. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Seminars in Oncology 1998;25:326-34.
3. Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al.Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology 1998;16(10):3345-52.
4. Bristow RE, Tomacruz RS, Armstrong DK, Timble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20:1248-59.
5. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic Oncology 2009;112(1):265-74.
6. Bucker HC, Guyatt GH, Griffith LE, Walter SD. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Epidemiology 1997;Vol. 50(No. 6):683-91.
7. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer . Obstetrics and Gynecology Clinics of North America 1994;21:167-78.
8. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (http://ctep.cancer.gov/forms/CTCAEv3.pdf) August 9th 2006.
9. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds) editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
10. Delgado G, Oram DH, Petril ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecologic Oncology 1984;18:293-8.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
12. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-53.
13. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J et al and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61-v118.
14. Ferrero A, Logrippo V, Fuso L, Perotto S, Daniele A, Zola P. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer. Internnational Journal of Gynecologic Cancer 2009;19(9):1529-34.
15. Gadducci A, Lacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecologic Oncology 2000;79(3):344-9.
16. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon 2004.
17. Goff BA, Mander L, Muntz HG. Ovarian carcinoma diagnosis. Cancer 2000;89(10):2068-75.
18. Gonzalez-Martin AA, CIavo E, Bover I, Rubio J, Arcusa A, Casado A. Randomized phaseII study of carboplatin versus paclitaxel-carboplatin in platinum sensitive recurrent advanced ovarian carcinoma with assessment of quality of life. Proceedings of the American Society of Clinical Oncology 2003;22:abs 1812.
19. Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecologic Oncology 2005;97(1):74-9.
20. Hacker NF, Berek JS, Lagasse CD, Neiberg RK, Elashoff RM. Primarycytoreductive surgery for epithelial ovarian cancer. Obstetrics and Gynecology 1983;61:413-20.
21. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al.Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)DESKTOP OVAR Trial. Annals of Surgical Oncology 2006;13(12):1702-10.
22. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Reviews in Anticancer Therapy 2010;10(1):81-8.
23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
24. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
25. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al.The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub optimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;70:974-80.
26. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents, Volume VIII. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB editor(s). IARC Scientific Publication No. 155. Lyon: IARC Scientific Publication, 2002.
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer Statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
28. Johnson NP, Selman T, Zamora J, Khan KS. Gynaecologic surgery from uncertainty to science: evidence-based surgery is no passing fad. Reproduction Advanced Access 2008.
29. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al.Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. Journal of Clinical Oncology 2004;22(15):3120-5.
30. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. International Journal of Gynecological Cancer 2009;S2:S63-7.
31. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecologic Oncology 2004;95(2):273-280.
32. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, BarakatR, Markman M, Randall M editor(s). Principles and Practice of Gynecologic Oncology. 4th Edition. Philadelphia, PA: Lippincott-Raven Publishers, 2005:895-987.
33. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
34. Parmar MK, Ledermann JA, Colombo N, du Bios A, Delaloye JF, Kristensen GB. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. the ICON4/AGO-OVAR-2-2 trial. Lancet 2003;361:2099-2106.
35. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukaso Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in Stage III and IV ovarian carcinoma. Journal of Clinical Oncology 1988;6:983-9.
36. Santillan A, Karam AK, Li AJ, Giuntoli R, Gardner GJ, Cass L, et al.Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecologic Oncology 2007;104:686-90.
37. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2001;83:504-12.
38. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of tumor pathology. Vol. fascicle 23 3rd series, Washington: Armed Forces Institute of Pathology, 1998:1-168.
39. Selinger G, Muelier LP, Kegal T, Kantekhardt EJ, Grothey A, Gros R, et al.Phase 2 trial of docetaxel, gemcitabine and oxliplatin combination in platinum-pretreated epithelial ovarian cancer. International Journal of Gynecological Cancer 2009;19(9):1529-34.
40. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889-92.
41. Smith LH, Morris CR, Yasmeen S. Ovarian cancer: can we make the clinical diagnosis earlier. Cancer 2005;104(7):1398-407.
42. Tay E-H, Grant PT, Gebski V, Hacker NF. Secondary Cytoreductive Surgery for RecurrentEpithelial Ovarian Cancer. Obstetrics and Gynecology 2002;99:1008-13.
43. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2007;106(3):482-87.
44. Weber B, Lortholary A, Mayer F, Bourgeois H, Orfeuvre H, Combe M, et al.Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Research 2009 Oct;29(10):4195-200.
45. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al.Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006;107(1):83-9.